Vistagen Therapeutics, Inc.
VTGN· Nasdaq
VTGNVistagen Therapeutics, Inc.
Filed Nov 19, 2014 · 10-Q · 50 days after period end · 0001415889-14-003624
| Metric | Q2 2015 | Q2 2014 | Q2 2010 |
|---|---|---|---|
| Revenue | — | — | $399.58K |
| Net Income | -$2.02M | -$1.46M | -$1.57M |
| EPS Diluted | -$1.90 | -$1.37 | -$0.30 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Vistagen Therapeutics, Inc. · CIK 1411685 · Engraved from SEC EDGAR
ended Sep 30, 2014 · filed Nov 19, 2014 · 50 d after period end
